



Market Announcement

1 August 2023

BOD Science Limited (ASX: BOD) – Trading Halt

Description

The securities of BOD Science Limited ('BOD') will be placed in trading halt at the request of BOD, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Thursday, 3 August 2023 or when the announcement is released to the market.

Issued by

Lisa Banh

Senior Adviser, Listings Compliance



1 August 2023

ASX Compliance Pty Ltd
20 Bridge Street
Sydney NSW 2000

By email: tradinghaltssydney@asx.com.au

**Bod Science Limited (ASX: BOD)
Request for Trading Halt**

Pursuant to Listing Rule 17.1, Bod Science Limited ACN 601 225 441 (the **Company** or **BOD**) requests that ASX grant an immediate trading halt of BOD's ordinary shares for a total of two trading days commencing pre-open on Tuesday, 1 August 2023.

In accordance with Listing Rule 17.1, we advise that:

1. the trading halt is requested in connection with a capital raising to be undertaken by the Company;
2. the trading halt is required to enable the capital raising to be undertaken in an orderly manner;
3. BOD requests that the trading halt remain in place until the earlier of such time as it makes an announcement to the market in relation to the outcome of the capital raising and the commencement of trading on Thursday, 3 August 2023; and
4. BOD is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market or ASX about the trading halt.

This trading halt request has been approved by the Board of Directors of Bod Science Limited.

About Bod Science

Bod Science (ASX:BOD) is a cannabis focused drug development and product innovation company.

Bod is focused on progressing research and development with a defined clinical trial pathway to commercialise and deliver premium, scientifically proven and trusted products for patients and consumers.

The Company has a number of existing partnerships with large corporate companies and collaborations with leading research organisations to advance the use of Cannabis related medicines with therapeutic indications.

For more information please contact:

Jo Patterson
Chief Executive Officer
Info@bodaustralia.com
+61 2 9199 5018

Amalie Schreurs
White Noise Communications
amalie@whitenoisecomms.com
+61 431 636 033